Checkpoint Therapeutics Announces Issuance of Two New Patents for EGFR Inhibitor CK-101

NEXT STORY
Hemispherx Biopharma Announces Significant Progress in its Ampligen Pancreatic Cancer Program and Multiple Ampligen+Checkpoint Blockade Immuno-Oncology Programs
PREV STORY
Oncology Venture rearranges its financing agreement with EHGOS (Alpha Blue Ocean)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

INNATE PHARMA : Promising anti-tumor activity of monalizumab with cetuximab in SCCHN

author_avatar
NASDAQ Market News

Novartis erzielt 2019 ein starkes Umsatzwachstum, Margen-steigerungen und bahnbrechende Innovationen mit der Markt¬einführung fünf neuer Wirkstoffe

author_avatar
NASDAQ Market News

Direct-to-Patient Market Worth US$67,897 Million by 2031. Visiongain Research Inc.

author_avatar
NASDAQ Market News